Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02475681
Registration number
NCT02475681
Ethics application status
Date submitted
12/06/2015
Date registered
19/06/2015
Date last updated
29/05/2024
Titles & IDs
Public title
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
Query!
Scientific title
A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acalabrutinib (ACP-196) in Combination With Obinutuzumab, and Acalabrutinib Monotherapy in Subjects With Previously Untreated CLL
Query!
Secondary ID [1]
0
0
2014-005582-73
Query!
Secondary ID [2]
0
0
ACE-CL-007
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ElevateTN
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Chronic Lymphocytic Leukemia
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Leukaemia - Chronic leukaemia
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Acalabrutinib
Treatment: Drugs - Obinutuzumab
Treatment: Drugs - Chlorambucil
Active Comparator: Arm A - Obinutuzumab in Combination with Chlorambucil - Obinutuzumab IV infusions will be administered over a total of 6 treatment cycles starting at Cycle 1 Day 1. Chlorambucil will be orally administered on Days 1 and 15 of Cycles 1 through 6.
Experimental: Arm B - Acalabrutinib in Combination with Obinutuzumab - Obinutuzumab IV infusions will be administered over a total of 6 treatment cycles starting at Cycle 2 Day 1. Acalabrutinib (ACP-196) will be orally administered starting on Cycle 1 Day 1. Daily administration of Acalabrutinib (ACP-196) will continue until disease progression or unacceptable toxicity.
Experimental: Arm C - Acalabrutinib Monotherapy - Acalabrutinib (ACP-196) will be orally administered on Cycle 1 Day 1 until disease progression or unacceptable toxicity.
Treatment: Drugs: Acalabrutinib
Treatment: Drugs: Obinutuzumab
Treatment: Drugs: Chlorambucil
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-free Survival by IRC (Independent Review Committee) Assessment in Arm A Compared to Arm B
Query!
Assessment method [1]
0
0
To evaluate the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with acalabrutinib in combination with obinutuzumab (Arm B) based on IRC assessment of progression-free survival (PFS) per International Workshop on Chronic Lymphocytic Leukemia criteria (IWCLL; Hallek et al. 2008) with incorporation of the clarification for treatment-related lymphocytosis (Cheson et al. 2012), hereafter referred to as IWCLL 2008 criteria, in subjects with previously untreated CLL. PFS, defined as the time from date of randomization to the date of first IRC-assessed disease progression or death due to any cause, whichever comes first.
Query!
Timepoint [1]
0
0
IRC assessments were done from randomization date until disease progression or death or IRC discontinuation date on 08Feb2019 (as the IA based on this data cutoff date showed the study crossing superiority boundary) whichever comes first up to 40 months.
Query!
Secondary outcome [1]
0
0
Progression-free Survival by IRC Assessment Arm A Versus Arm C
Query!
Assessment method [1]
0
0
To evaluate the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with acalabrutinib monotherapy (Arm C) based on IRC assessment of progression-free survival (PFS) per International Workshop on Chronic Lymphocytic Leukemia criteria (IWCLL; Hallek et al. 2008) with incorporation of the clarification for treatment-related lymphocytosis (Cheson et al. 2012), hereafter referred to as IWCLL 2008 criteria, in subjects with previously untreated CLL. PFS, defined as the time from date of randomization to the date of first IRC-assessed disease progression or death due to any cause, whichever comes first.
Query!
Timepoint [1]
0
0
IRC assessments were done from randomization date until disease progression or death or IRC discontinuation date on 08Feb2019 (as the IA based on this data cutoff date showed the study crossing superiority boundary) whichever comes first up to 40 months.
Query!
Secondary outcome [2]
0
0
IRC-assessed Objective Response Rate (ORR) in Arm A Versus Arm B and Arm A Versus Arm C
Query!
Assessment method [2]
0
0
ORR was defined as the proportion of subjects who achieved a best response of CR, CRi, nPR, or PR at or before initiation of subsequent anticancer therapy. ORR including PRL was defined as the proportion of subjects who achieved a best response of CR, CRi, nPR, PR or PRL at or before initiation of subsequent anticancer therapy
Query!
Timepoint [2]
0
0
IRC assessments were done from randomization date until disease progression or death or IRC discontinuation date on 08Feb2019 (as the IA based on this data cutoff date showed the study crossing superiority boundary) whichever comes first up to 40 months.
Query!
Secondary outcome [3]
0
0
Time to Next Treatment (TTNT) in Arm A Versus Arm B and Arm A Versus Arm C
Query!
Assessment method [3]
0
0
TTNT was defined as the time from randomization to start date of non-protocol specified subsequent anticancer therapy for CLL or death due to any cause, whichever came first. TTNT was analyzed in the same fashion as that for the primary efficacy analysis
Query!
Timepoint [3]
0
0
From randomization date to start of non-protocol specified subsequent anticancer therapy for CLL or death due to any cause, whichever came first assessed up to 40 months of follow-up.
Query!
Secondary outcome [4]
0
0
Overall Survival (OS) in Arm A Versus Arm B and Arm A Versus Arm C
Query!
Assessment method [4]
0
0
OS was defined as the time from the date of randomization to death due to any cause.
Query!
Timepoint [4]
0
0
From randomization date until death, withdrawal by subject, lost to follow-up, or by analysis data cut off date on 08Feb2019 whichever comes first up to 40 months of follow-up.
Query!
Eligibility
Key inclusion criteria
Inclusion Criteria
1. Men and women:
a. = 65 years of age OR b. > 18 and < 65 years of age, provided that they meet at
least one of the following criteria: i. Creatinine clearance 30 to 69 mL/min using the
Cockcroft-Gault equation ii. A score higher than 6 on the CIRS-G (Appendix L).
2. ECOG performance status of 0, 1, or 2.
3. Diagnosis of CD20+ CLL that meets published diagnostic criteria (Hallek 2008):
1. Monoclonal B cells (either kappa or lambda light chain restricted) that are
clonally co-expressing = 1 B-cell marker (CD19, CD20, or CD23) and CD5.
2. Prolymphocytes may comprise = 55% of blood lymphocytes.
3. Presence of = 5 x 109 B lymphocytes/L (5000 µL) in the peripheral blood (at any
point since diagnosis)
4. Active disease meeting = 1 of the following IWCLL 2008 criteria for requiring
treatment:
1. Evidence of progressive marrow failure as manifested by the development of, or
worsening of, anemia (hemoglobin < 10 g/dL) and/or thrombocytopenia (platelets <
100,000/µL).
2. Massive (i.e., = 6 cm below the left costal margin), progressive, or symptomatic
splenomegaly.
3. Massive nodes (i.e., = 10 cm in the longest diameter), progressive, or
symptomatic lymphadenopathy.
4. Progressive lymphocytosis with an increase of > 50% over a 2-month period or a
LDT of < 6 months. LDT may be obtained by linear regression extrapolation of ALC
obtained at intervals of 2 weeks over an observation period of 2 to 3 months. In
subjects with initial blood lymphocyte counts of < 30 x 109/L (30,000/µL), LDT
should not be used as a single parameter to define indication for treatment. In
addition, factors contributing to lymphocytosis or lymphadenopathy other than CLL
(e.g., infections) should be excluded.
5. Autoimmune anemia and/or thrombocytopenia that is poorly responsive to standard
therapy.
6. Constitutional symptoms documented in the subject's chart with supportive
objective measures, as appropriate, defined as = 1 of the following
disease-related symptoms or signs:
i. Unintentional weight loss = 10% within the previous 6 months before Screening.
ii. Significant fatigue (i.e., ECOG performance status 2; inability to work or perform
usual activities).
iii. Fevers higher than 100.5°F or 38.0°C for 2 or more weeks before Screening without
evidence of infection.
iv. Night sweats for > 1 month before Screening without evidence of infection.
5. This criterion was deleted as of Protocol Amendment 3.
6. Meet the following laboratory parameters:
1. ANC = 750 cells/µL (0.75 x 109/L), or = 500 cells/µL (0.50 x 109/L) in subjects
with documented bone marrow involvement, and independent of growth factor support
7 days before assessment.
2. Platelet count = 50,000 cells/µL (50 x 109/L), or = 30,000 cells/µL (30 x 109/L)
in subjects with documented bone marrow involvement, and without transfusion
support 7 days before assessment. Subjects with transfusion-dependent
thrombocytopenia are excluded.
3. Serum AST and ALT/SGPT = 3.0 x ULN.
4. Total bilirubin = 1.5 x ULN.
5. Estimated creatinine clearance (i.e., eGFR using Cockcroft-Gault) = 30 mL/min
7. Able to receive all outpatient treatment, all laboratory monitoring, and all
radiologic evaluations.
8. Women who are sexually active and can bear children must agree to use highly effective
forms of contraception while on the study and for 2 days after the last dose of
acalabrutinib or 18 months after the last dose of obinutuzumab in combination with
chlorambucil, whichever is longer. Highly effective forms of contraception are defined
in Section 6.4.4.
9. Men who are sexually active and can beget children must agree to use highly effective
forms of contraception during the study and for 90 days after the last dose of
obinutuzumab or chlorambucil, whichever is later. Highly effective forms of
contraception are defined in Section 6.4.4.
10. Men must agree to refrain from sperm donation during the study and for 90 days after
the last dose of obinutuzumab or chlorambucil, whichever is later.
11. Must be willing and able to adhere to the study visit schedule, understand and comply
with other protocol requirements, and provide written informed consent and
authorization to use protected health information (in accordance with national and
local subject privacy regulations). Note vulnerable subjects, as defined in
International Conference on Harmonisation (ICH) GCP, are not allowed on this protocol
(e.g., prisoners or institutionalized subjects).
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Any prior systemic treatment for CLL (note: Prior localized radiotherapy is allowed).
2. Known CNS lymphoma or leukemia.
3. Known prolymphocytic leukemia or history of, or currently suspected, Richter's
syndrome.
4. Missing or incomplete documentation of FISH results reflecting the presence or absence
of 17p del and the percentage of cells with the deletion in subject records before
randomization.
5. Uncontrolled AIHA or ITP defined as declining hemoglobin or platelet count secondary
to autoimmune destruction within the screening period or requirement for high doses of
steroids (> 20 mg daily of prednisone daily or equivalent).
6. Corticosteroid use > 20 mg within 1 week before first dose of study drug, except as
indicated for other medical conditions such as inhaled steroid for asthma, topical
steroid use, or as premedication for administration of study drug or contrast. For
example, subjects requiring steroids at daily doses > 20 mg prednisone equivalent
systemic exposure daily, or those who are administered steroids for leukemia control
or WBC count lowering are excluded.
7. Major surgery within 4 weeks before first dose of study drug.
8. History of prior malignancy except for the following:
1. Malignancy treated with curative intent and with no evidence of active disease
present for more than 3 years before Screening and felt to be at low risk for
recurrence by treating physician.
2. Adequately treated lentigo maligna melanoma without current evidence of disease
or adequately controlled non-melanomatous skin cancer.
3. Adequately treated cervical carcinoma in situ without current evidence of
disease.
9. Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias,
congestive heart failure, or myocardial infarction within 6 months of screening, or
any Class 3 or 4 cardiac disease as defined by the New York Heart Association
Functional Classification, or QTc > 480 msec at screening.
10. Unable to swallow capsules or malabsorption syndrome, disease significantly affecting
gastrointestinal function, or resection of the stomach or small bowel or gastric
bypass, symptomatic inflammatory bowel disease, or partial or complete bowel
obstruction.
11. Uncontrolled active systemic fungal, bacterial, viral, or other infection (defined as
exhibiting ongoing signs/symptoms related to the infection and without improvement,
despite appropriate antibiotics or other treatment) or ongoing intravenous
anti-infective treatment.
12. Known history of infection with HIV. 13. Vaccinated with live, attenuated vaccines
within 4 weeks of first dose of study drug.
14. Serologic status reflecting active hepatitis B or C infection. Subjects with hepatitis
B core antibody positive who are surface antigen negative or who are hepatitis C antibody
positive will need to have a negative PCR result before randomization. Those who are
hepatitis B surface antigen positive or hepatitis B PCR positive and those who are
hepatitis C PCR positive will be excluded.
15. History of stroke or intracranial hemorrhage within 6 months before randomization.
16. Known history of a bleeding diathesis (e.g., hemophilia, von Willebrand disease).
17. Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists
(e.g., phenprocoumon) within 7 days of first dose of study drug.
18. Requires treatment with proton-pump inhibitors (e.g., omeprazole, esomeprazole,
lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole).
19. Breast feeding or pregnant. 20. Current life-threatening illness, medical condition, or
organ system dysfunction which, in the Investigator's opinion, could compromise the
subject's safety or put the study at risk.
21. Concurrent participation in another therapeutic clinical trial. 22. Requires treatment
with a strong CYP3A inhibitor/inducer. 23. Presence of a gastrointestinal ulcer diagnosed
by endoscopy within 3 months before screening.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people assessing the outcomes
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
26/06/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
30/09/2025
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
535
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Research Site - Darlinghurst
Query!
Recruitment hospital [2]
0
0
Research Site - Frankston
Query!
Recruitment hospital [3]
0
0
Research Site - Geelong
Query!
Recruitment hospital [4]
0
0
Research Site - South Brisbane
Query!
Recruitment hospital [5]
0
0
Research Site - Waratah NSW
Query!
Recruitment hospital [6]
0
0
Research Site - Wollongong
Query!
Recruitment hospital [7]
0
0
Research Site - Woodville
Query!
Recruitment postcode(s) [1]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [2]
0
0
3199 - Frankston
Query!
Recruitment postcode(s) [3]
0
0
3220 - Geelong
Query!
Recruitment postcode(s) [4]
0
0
QLD 4101 - South Brisbane
Query!
Recruitment postcode(s) [5]
0
0
2298 - Waratah NSW
Query!
Recruitment postcode(s) [6]
0
0
2500 - Wollongong
Query!
Recruitment postcode(s) [7]
0
0
5011 - Woodville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
District of Columbia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Indiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kansas
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Kentucky
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Louisiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Maryland
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Minnesota
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Montana
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New Jersey
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New York
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Ohio
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Tennessee
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Texas
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Utah
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Virginia
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Washington
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Wisconsin
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Brugge
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Brussels
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
Bruxelles
Query!
Country [26]
0
0
Belgium
Query!
State/province [26]
0
0
Ghent
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Kortrijk
Query!
Country [28]
0
0
Belgium
Query!
State/province [28]
0
0
Leuven
Query!
Country [29]
0
0
Belgium
Query!
State/province [29]
0
0
Roeselare
Query!
Country [30]
0
0
Belgium
Query!
State/province [30]
0
0
Wilrijk
Query!
Country [31]
0
0
Belgium
Query!
State/province [31]
0
0
Yvoir
Query!
Country [32]
0
0
Brazil
Query!
State/province [32]
0
0
Barretos
Query!
Country [33]
0
0
Brazil
Query!
State/province [33]
0
0
Florianopolis
Query!
Country [34]
0
0
Brazil
Query!
State/province [34]
0
0
Passo Fundo
Query!
Country [35]
0
0
Brazil
Query!
State/province [35]
0
0
Porto Alegre
Query!
Country [36]
0
0
Brazil
Query!
State/province [36]
0
0
Sao Paulo
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
British Columbia
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
Nova Scotia
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
Quebec City
Query!
Country [40]
0
0
Canada
Query!
State/province [40]
0
0
Saint John
Query!
Country [41]
0
0
Canada
Query!
State/province [41]
0
0
Winnipeg
Query!
Country [42]
0
0
Chile
Query!
State/province [42]
0
0
Santiago
Query!
Country [43]
0
0
Chile
Query!
State/province [43]
0
0
Temuco
Query!
Country [44]
0
0
Colombia
Query!
State/province [44]
0
0
Medellin
Query!
Country [45]
0
0
Colombia
Query!
State/province [45]
0
0
Monteria
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Bobigny
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Dijon
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Pierre-Benite
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Strasbourg Cedex
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Villejuif
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Aschaffenburg
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Bielefeld
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Erlangen
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Heilbronn
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Warzburg
Query!
Country [56]
0
0
Hungary
Query!
State/province [56]
0
0
Budapest
Query!
Country [57]
0
0
Hungary
Query!
State/province [57]
0
0
Debrecen
Query!
Country [58]
0
0
Hungary
Query!
State/province [58]
0
0
Kaposvár
Query!
Country [59]
0
0
Hungary
Query!
State/province [59]
0
0
Szolnok
Query!
Country [60]
0
0
Israel
Query!
State/province [60]
0
0
Ashkelon
Query!
Country [61]
0
0
Israel
Query!
State/province [61]
0
0
Beer Sheva
Query!
Country [62]
0
0
Israel
Query!
State/province [62]
0
0
Haifa
Query!
Country [63]
0
0
Israel
Query!
State/province [63]
0
0
Jerusalem
Query!
Country [64]
0
0
Israel
Query!
State/province [64]
0
0
Nahariya
Query!
Country [65]
0
0
Israel
Query!
State/province [65]
0
0
Petah Tikvah
Query!
Country [66]
0
0
Israel
Query!
State/province [66]
0
0
Rehovot
Query!
Country [67]
0
0
Israel
Query!
State/province [67]
0
0
Tel Aviv
Query!
Country [68]
0
0
Israel
Query!
State/province [68]
0
0
Tel Hashomer
Query!
Country [69]
0
0
Israel
Query!
State/province [69]
0
0
Tiberias
Query!
Country [70]
0
0
Italy
Query!
State/province [70]
0
0
Alessandria
Query!
Country [71]
0
0
Italy
Query!
State/province [71]
0
0
Aviano
Query!
Country [72]
0
0
Italy
Query!
State/province [72]
0
0
Brescia
Query!
Country [73]
0
0
Italy
Query!
State/province [73]
0
0
Firenze
Query!
Country [74]
0
0
Italy
Query!
State/province [74]
0
0
Meldola
Query!
Country [75]
0
0
Italy
Query!
State/province [75]
0
0
Milano
Query!
Country [76]
0
0
Italy
Query!
State/province [76]
0
0
Parma
Query!
Country [77]
0
0
Italy
Query!
State/province [77]
0
0
Ravenna
Query!
Country [78]
0
0
Italy
Query!
State/province [78]
0
0
Rimini
Query!
Country [79]
0
0
Italy
Query!
State/province [79]
0
0
Rome
Query!
Country [80]
0
0
Italy
Query!
State/province [80]
0
0
Rozzano
Query!
Country [81]
0
0
Lithuania
Query!
State/province [81]
0
0
Kaunas
Query!
Country [82]
0
0
Lithuania
Query!
State/province [82]
0
0
Klaipeda
Query!
Country [83]
0
0
Lithuania
Query!
State/province [83]
0
0
Vilnius
Query!
Country [84]
0
0
New Zealand
Query!
State/province [84]
0
0
Auckland
Query!
Country [85]
0
0
New Zealand
Query!
State/province [85]
0
0
Otahuhu
Query!
Country [86]
0
0
New Zealand
Query!
State/province [86]
0
0
Tauranga
Query!
Country [87]
0
0
Poland
Query!
State/province [87]
0
0
Bydgoszcz
Query!
Country [88]
0
0
Poland
Query!
State/province [88]
0
0
Gdansk
Query!
Country [89]
0
0
Poland
Query!
State/province [89]
0
0
Gdynia
Query!
Country [90]
0
0
Poland
Query!
State/province [90]
0
0
Kraków
Query!
Country [91]
0
0
Poland
Query!
State/province [91]
0
0
Lodz
Query!
Country [92]
0
0
Poland
Query!
State/province [92]
0
0
Lublin
Query!
Country [93]
0
0
Poland
Query!
State/province [93]
0
0
Olsztyn
Query!
Country [94]
0
0
Poland
Query!
State/province [94]
0
0
Opole
Query!
Country [95]
0
0
Poland
Query!
State/province [95]
0
0
Slupsk
Query!
Country [96]
0
0
Spain
Query!
State/province [96]
0
0
Barcelona
Query!
Country [97]
0
0
Spain
Query!
State/province [97]
0
0
Madrid
Query!
Country [98]
0
0
Spain
Query!
State/province [98]
0
0
Majadahonda
Query!
Country [99]
0
0
Spain
Query!
State/province [99]
0
0
Santander
Query!
Country [100]
0
0
Sweden
Query!
State/province [100]
0
0
Gothenburg
Query!
Country [101]
0
0
Sweden
Query!
State/province [101]
0
0
Linkoping
Query!
Country [102]
0
0
Sweden
Query!
State/province [102]
0
0
Lund
Query!
Country [103]
0
0
Sweden
Query!
State/province [103]
0
0
Orebro
Query!
Country [104]
0
0
United Kingdom
Query!
State/province [104]
0
0
Bournemouth
Query!
Country [105]
0
0
United Kingdom
Query!
State/province [105]
0
0
Cambridge
Query!
Country [106]
0
0
United Kingdom
Query!
State/province [106]
0
0
Leeds
Query!
Country [107]
0
0
United Kingdom
Query!
State/province [107]
0
0
Leicester
Query!
Country [108]
0
0
United Kingdom
Query!
State/province [108]
0
0
London
Query!
Country [109]
0
0
United Kingdom
Query!
State/province [109]
0
0
Plymouth
Query!
Country [110]
0
0
United Kingdom
Query!
State/province [110]
0
0
Southampton
Query!
Country [111]
0
0
United Kingdom
Query!
State/province [111]
0
0
Truro
Query!
Country [112]
0
0
United Kingdom
Query!
State/province [112]
0
0
Wolverhampton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Acerta Pharma BV
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This Primary objective is evaluating the efficacy of obinutuzumab in combination with
chlorambucil (Arm A) compared with acalabrutinib in combination with obinutuzumab (Arm B) for
the treatment of previously untreated chronic lymphocytic leukemia (CLL). Secondary
objectives: 1) To evaluate the efficacy of obinutuzumab in combination with chlorambucil (Arm
A) versus acalabrutinib monotherapy (Arm C) based on IRC assessment of PFS per IWCLL 2008
criteria.
2)To compare obinutuzumab plus chlorambucil (Arm A) versus acalabrutinib plus obinutuzumab
(Arm B) and obinutuzumab plus chlorambucil (Arm A) versus acalabrutinib monotherapy (Arm C)
in terms of: IRC-assessed objective response rate (ORR); Tine to next treatment (TTNT);
Overall Survival (OS)
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02475681
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
AstraZeneca Clinical Study Information Center
Query!
Address
0
0
1-877-240-9479
[email protected]
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02475681
Download to PDF